AKT Signaling as a Novel Factor Associated with In Vitro Resistance of Human AML to Gemtuzumab Ozogamicin

• David B. Rosen,

  Affiliation Nodality Inc., South San Francisco, California, United States of America

  ⨯
• Kimberly H. Harrington,

  Affiliation Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America

  ⨯
• James A. Cordeiro,

  Affiliation Nodality Inc., South San Francisco, California, United States of America

  ⨯
• Ling Y. Leung,

  Affiliation Nodality Inc., South San Francisco, California, United States of America

  ⨯
• Santosh Putta,

  Affiliation Nodality Inc., South San Francisco, California, United States of America

  ⨯
• Norman Lacayo,

  Affiliation Division of Pediatric Hematology/Oncology, Stanford University School of Medicine, Palo Alto, California, United States of America

  ⨯
• George S. Laszlo,

  Affiliation Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America

  ⨯
• Chelsea J. Gudgeon,

  Affiliation Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America

  ⨯
• Donna E. Hogge,

  Affiliation Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, British Columbia, Canada

  ⨯
• Rachael E. Hawtin,

  Affiliation Nodality Inc., South San Francisco, California, United States of America

  ⨯
• Alessandra Cesano ,

  * E-mail: alessandra.cesano@nodality.com

  ¶Joint Senior Authors

  Affiliation Nodality Inc., South San Francisco, California, United States of America

  ⨯
• Roland B. Walter

  ¶Joint Senior Authors

  Affiliations Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America, Division of Hematology/Department of Medicine, University of Washington, Seattle, Washington, United States of America, Department of Epidemiology, University of Washington, Seattle, Washington, United States of America

  ⨯